Avoro Capital Advisors LLC increased its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 17.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,474,747 shares of the company’s stock after acquiring an additional 1,124,747 shares during the quarter. Kymera Therapeutics comprises about 5.6% of Avoro Capital Advisors LLC’s holdings, making the stock its 7th biggest holding. Avoro Capital Advisors LLC owned 0.09% of Kymera Therapeutics worth $581,610,000 at the end of the most recent reporting period.
Other large investors also recently modified their holdings of the company. SG Americas Securities LLC boosted its position in shares of Kymera Therapeutics by 169.1% in the fourth quarter. SG Americas Securities LLC now owns 22,693 shares of the company’s stock valued at $1,766,000 after acquiring an additional 14,261 shares during the period. Hudson Bay Capital Management LP boosted its position in shares of Kymera Therapeutics by 362.7% in the third quarter. Hudson Bay Capital Management LP now owns 23,134 shares of the company’s stock valued at $1,309,000 after acquiring an additional 18,134 shares during the period. Vanguard Group Inc. boosted its position in shares of Kymera Therapeutics by 15.6% in the fourth quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock valued at $487,685,000 after acquiring an additional 845,922 shares during the period. Eagle Health Investments LP bought a new position in shares of Kymera Therapeutics in the fourth quarter valued at approximately $10,606,000. Finally, Holocene Advisors LP bought a new position in shares of Kymera Therapeutics in the third quarter valued at approximately $47,563,000.
Wall Street Analysts Forecast Growth
KYMR has been the subject of a number of analyst reports. BTIG Research cut their price objective on shares of Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. Piper Sandler raised their price objective on shares of Kymera Therapeutics from $125.00 to $140.00 and gave the company an “overweight” rating in a research report on Thursday, February 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Tuesday, April 21st. UBS Group lifted their target price on shares of Kymera Therapeutics from $90.00 to $128.00 and gave the company a “buy” rating in a research report on Tuesday, March 3rd. Finally, Brookline Capital Markets reiterated a “buy” rating on shares of Kymera Therapeutics in a research report on Monday, June 8th. One analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $117.14.
Kymera Therapeutics Price Performance
Shares of Kymera Therapeutics stock opened at $87.44 on Wednesday. Kymera Therapeutics, Inc. has a 1 year low of $36.65 and a 1 year high of $103.00. The firm has a market cap of $7.19 billion, a PE ratio of -24.49 and a beta of 2.02. The company has a 50 day simple moving average of $82.90 and a two-hundred day simple moving average of $80.59.
Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) last announced its earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.18. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The business had revenue of $34.37 million during the quarter, compared to analyst estimates of $8.27 million. During the same period in the previous year, the business posted ($0.82) earnings per share. Kymera Therapeutics’s revenue for the quarter was up 55.5% on a year-over-year basis. As a group, research analysts anticipate that Kymera Therapeutics, Inc. will post -3.25 earnings per share for the current year.
Insider Activity at Kymera Therapeutics
In other news, Director Bruce Booth sold 5,900 shares of the business’s stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $89.96, for a total value of $530,764.00. Following the completion of the sale, the director directly owned 5,641 shares in the company, valued at approximately $507,464.36. The trade was a 51.12% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jeremy G. Chadwick sold 4,279 shares of the business’s stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $81.58, for a total transaction of $349,080.82. Following the completion of the sale, the chief operating officer owned 44,018 shares of the company’s stock, valued at approximately $3,590,988.44. The trade was a 8.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 234,357 shares of company stock valued at $19,072,496. Company insiders own 15.98% of the company’s stock.
Kymera Therapeutics Profile
Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.
The company’s pipeline emphasizes immunology and oncology.
Featured Articles
- Five stocks we like better than Kymera Therapeutics
- Gravity Check: Houston, SpaceX Has a Valuation Problem
- Strategy’s Bitcoin Rally Has a Hidden Engine
- Okta’s AI Moment May Be Bigger Than Investors Realize
- 3 Rate-Ready Stocks for the New Fed Chair’s First Big Test
Want to see what other hedge funds are holding KYMR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report).
Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
